Welcome to the e-CCO Library!

P509: IBD cancer and serious infections in Europe (I-CARE): a European prospective observational study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

The I-CARE Study Group

Created: Wednesday, 20 February 2019, 10:36 AM
P509: Influence of concomitant immunosuppresives in retention rate in Crohn´s Disease patients under ustekinumab in the SUSTAIN Study
Year: 2021
Source: ECCO'21 Virtual
Authors: Chaparro, M.(1);Bastón Rey, I.(2);Fernández-Salgado, E.(3);González García, J.(4);Ramos, L.(5);Diz-Lois Palomares, M.T.(6);Argüelles, F.(7);Iglesias Flores, E.(8);Cabello, M.(9);Rubio Iturria, S.(10);Núñez Ortiz, A.(11);Charro, M.(12);Ginard, D.(13);Dueñas Sadornil, C.(14);Merino Ochoa, O.(15);Busquets, D.(16);Iyo, E.(17);Gutiérrez Casbas, A.(18);Ramírez de la Piscina, P.(19);Boscá-Watts, M.M.(20);Arroyo, M.(21);García, M.J.(22);Hinojosa, E.(23);Gordillo, J.(24);Martínez Montiel, P.(25);Velayos Jiménez, B.(26);Quílez Ivorra, C.(27);Vázquez Morón, J.M.(28);Huguet, J.M.(29);González Lama, Y.(30);Muñagorri Santos, A.I.(31);Amo, V.M.(32);Martín Arranz, M.D.(33);Bermejo, F.(34);Martínez Cadilla, J.(35);Fradejas Salazar, P.(36);Novella, C.(37);Vispo, E.(37);Barreiro-de Acosta, M.(2);Gisbert, J.P.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P509: Long-term outcomes in biologic-treated perianal Crohn’s fistula
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Adegbola1*, W.Y. Mak2, K. Sahnan1, P. Tozer1,3, P. Bassett4, S. Hiles5, R. Phillips1, J. Warusavitarne1,3, O. Faiz1,3, A. Hart1,2

Created: Thursday, 21 February 2019, 9:14 AM
P509: Long-term outcomes of adalimumab in patients with Crohn’s disease: Can a doubled dose of adalimumab improve outcomes?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Kanazawa*1, K. Yokoyama1, Y. Matsumoto1, K. Kawagishi1, M. Mukae1, M. Kubota1, K. Kobayashi1, W. Koizumi1

Created: Friday, 22 February 2019, 9:41 AM
P509: Surgery and biologic prescription rates for Crohn's disease in Lothian, Scotland; an updated population-based cohort study.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Jenkinson, P.(1)*;Plevris, N.(2);Lyons, M.(2);Gros Alcalde, B.(2);Derikx, L.(2);Constantine-Cooke, N.(3);Arnott, I.(2);Jones, G.(4);Lees, C.(2);
Created: Friday, 14 July 2023, 11:05 AM
P509: What is the effect of inflammatory bowel disease on sedation rates at colonoscopy?
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Walshe*, C. Moran, G. Horgan, G. Cullen, H. Mulcahy, G. Doherty

Created: Friday, 22 February 2019, 9:49 AM
P510 Dose escalation of subcutaneous vedolizumab in patients with ulcerative colitis: A post hoc analysis of the VISIBLE trial data
Year: 2020
Source:

ECCO'20 Vienna

Authors:

W. Sandborn1, D. Wolf2, G. D’haens3, J. Jansson4, J. Chen5, S. Uddin5, N. Candela6, K. Lasch6, K. Kisfalvi5

Created: Thursday, 30 January 2020, 10:12 AM
P510: Assessment of study group – patients with inflammatory bowel disease, treated with monoclonal anti-TNF alpha: a multicenter, prospective cohort observational study, Satimos – preliminary report in pediatric population
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Jarzebicka D.*1, Sieczkowska J.1, Borys-Iwanicka A.2, Korlatowicz-Bilar A.3, Szaflarska-Popławska A.4, Grzybowska-Chlebowczyk U.5, Łazowska-Przeorek I.6, Daniluk U.7, Korczowski B.8, Sordyl B.9, Szczepanik M.10, Landowski P.11, Plocek A.12, Bąk-Drabik K.13, Zagόrowicz E.14, Kierkus J.1

Created: Wednesday, 20 February 2019, 10:36 AM
P510: Comparative effectiveness of Ustekinumab against other biologics in Inflammatory Bowel Disease: a propensity score analysis.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Matos Coelho Bernardo, S.(1)*;Fernandes, S.(1);Serrazina, J.(1);Rodrigues, I.(1);Botto, I.(1);Bronze, S.(1);Gonçalves, A.R.(1);Valente, A.(1);Santos, P.M.D.(1);Tato Marinho, R.(1);Correia, L.(1);
Created: Friday, 14 July 2023, 11:05 AM
P510: Comparative efficacy of biologic therapies for inducing response and remission in fistulizing Crohn’s disease; Systematic Review and Network Meta-analysis
Year: 2022
Source: ECCO'22
Authors: Shehab, M.(1);Alrashed, F.(2);Heron, V.(3);Restellini, S.(4);Bessissow, T.(5);
Created: Friday, 11 February 2022, 3:56 PM
P510: Hypergammaglobulinemia, hypoalbuminemia, and elevated CRP levels are predictors of a secondary loss of response to anti-TNFα therapy in IBD
Year: 2018
Source: ECCO '18 Vienna
Authors:

F. Schoenefuss*, P. Hoffmann

Created: Thursday, 21 February 2019, 9:14 AM
P510: Infliximab in the very young: it is all about the dosing – a multi-centre study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Jongsma*1, D. Winter1, H. Huynh2, L. Norsa3, S. Hussey4, K-l. Kolho5, J. Bronsky6, A. Assa7, S. Cohen8, R. Lev-Tzion9, S. van Biervliet10, T. de Meij11, D. Shouval12, E. Wine2, V. Wolters13, A. Christiaens14, C. Martinez-Vinson15, L. de Ridder1

Created: Friday, 22 February 2019, 9:41 AM
P510: Postoperative enterocoutaneous fistula after surgery for Crohn’s disease performed in a tertiary centre over 15 years: analysis of the long-term outcomes and predictors of fistula closure
Year: 2021
Source: ECCO'21 Virtual
Authors: Parlanti, D.(1);Poggioli, G.(1);Cardelli, S.(1);Tanzanu, M.(1);Boschi, L.(1);Rottoli, M.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P510: Skin anergy and latent tuberculosis in inflammatory bowel disease patients
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

C. Herrera de Guise*, V. Robles, N. Borruel, E. Navarro, F. Casellas

Created: Friday, 22 February 2019, 9:49 AM
P511 Association of ustekinumab serum concentrations and clinical outcomes: results from the mUST-DECIDE trial
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Bressler1, B. Sattin2, M.A. Williamson2, R. Khanna3, C.H. Seow4, D. Dajnowiec2, K. Karra2, L.L. Gao5, W. Afif6, mUST-Decide

Created: Thursday, 30 January 2020, 10:12 AM
P511: Baseline characteristics of ulcerative colitis patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (01)
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Wolf D.*1, Lewis J.D.2, Siegmund B.3, Lichtenstein G.2, Sebastian S.4, Siegel C.A.5, Louis E.6, Haas T.7, Nedd K.8, Subramanian S.9, Aguilar H.10, Egan L.11, Gasche C.12, Doherty G.13, Lobo A.14, Spearman D.15, Patel A.16, Moparty R.17, Brookes M.18, Hebuterne X.19, Moum B.20, Dolin P.21

Created: Wednesday, 20 February 2019, 10:36 AM
P511: Disease-specific risk factors for malnutrition development in IBD
Year: 2021
Source: ECCO'21 Virtual
Authors: Einav, L.(1);Hirsch, A.(1,2);Ron, Y.(1,2);Aviv Cohen, N.(1,2);Anbar, R.(1,3);Lahav, S.(2);Maharshak, N.(1,2);Fliss Isakov, N.(1,2);
Created: Wednesday, 2 June 2021, 4:12 PM
P511: Early prediction of steroid failure in acute severe ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

M.C. Choy1,2,3*, K. Boyd4, R. Burder4, A. Gorelik5, R. Nallas6, J. Horvath6, Q. Lam6, N. Crinis6, D. Van Langenberg7, M. Sparrow8, W. Connell3, K. Visvanathan3,9, P. De Cruz1,2

Created: Thursday, 21 February 2019, 9:14 AM
P511: Efficacy of Crohn's Disease exclusion diet in different clinical scenarios in paediatrics; at onset of the disease and after loss of response to biological therapy
Year: 2022
Source: ECCO'22
Authors: Jijón, M.C.(1);Pujol-Muncunill, G.(1);Lozano Ruf, A.(1);Vila Miravet, V.(1);Alvarez Carnero, L.(1);García Arenas, D.(1);Egea Castillo, N.(1);Martín de Carpi, J.(1);
Created: Friday, 11 February 2022, 3:56 PM
P511: Evaluation of home faecal calprotectin testing to aid remote management and enhanced self-management of Inflammatory Bowel Disease.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Allen, K.(1)*;Munuswamy, P.(2);
Created: Friday, 14 July 2023, 11:05 AM